Cargando…

No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

To characterize the use of olodaterol and indacaterol in clinical practice and to quantify the off-label use in asthma. Drug utilization study of new users of olodaterol or indacaterol between 2014 and 2017 in the PHARMO Database Network in the Netherlands, the Danish population registers, and the I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rebordosa, Cristina, Houben, Eline, Laugesen, Kristina, Bothner, Ulrich, Montonen, Jukka, Aguado, Jaume, Overbeek, Jetty A., Ehrenstein, Vera, Asmar, Joelle, Wallace, Laura, Gilsenan, Alicia W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968970/ https://www.ncbi.nlm.nih.gov/pubmed/31953521 http://dx.doi.org/10.1038/s41598-019-57397-5

Ejemplares similares

Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists
por: Rebordosa, Cristina, et al.
Publicado: (2022)

Ophthalmic nepafenac use in the Netherlands and Denmark
por: Margulis, Andrea V, et al.
Publicado: (2017)

Systematic review comparing LABA, olodaterol, and indacaterol: limitations
por: Donohue, James F
Publicado: (2014)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study
por: Forns, Joan, et al.
Publicado: (2022)

Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database
por: Quint, Jennifer K., et al.
Publicado: (2021)

A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD
por: Andreas, Stefan, et al.
Publicado: (2020)

Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies
por: Ferguson, Gary T., et al.
Publicado: (2020)

Prevalence of chronic kidney disease in the Netherlands and its cardiovascular and renal complications
por: Vervloet, Marc G., et al.
Publicado: (2023)

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
por: Hsieh, Meng-Jer, et al.
Publicado: (2022)

Long-term safety of tiotropium/olodaterol Respimat(®) in patients with moderate-to-very severe COPD and renal impairment in the TONADO(®) studies
por: LaForce, Craig, et al.
Publicado: (2018)

Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022)

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease
por: Bai, Chunxue, et al.
Publicado: (2017)

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
por: van Boven, Job FM, et al.
Publicado: (2016)

Indacaterol: a comprehensive review
por: Rossi, Andrea, et al.
Publicado: (2013)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands
por: Morales, Daniel R., et al.
Publicado: (2020)

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Social isolation and all-cause mortality: a population-based cohort study in Denmark
por: Laugesen, Kristina, et al.
Publicado: (2018)

Safety of indacaterol in the treatment of patients with COPD
por: Donohue, James F, et al.
Publicado: (2011)

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat(®) device for maintenance treatment of COPD: comparison with the long-acting β(2)-agonist formoterol
por: Koch, Andrea, et al.
Publicado: (2017)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Completeness and Representativeness of the PHARMO General Practitioner (GP) Data: A Comparison with National Statistics
por: Overbeek, Jetty A, et al.
Publicado: (2023)

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD
por: Andreas, Stefan, et al.
Publicado: (2020)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD
por: Andreas, Stefan, et al.
Publicado: (2020)

The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands
por: Schildkraut, Jodie Anne, et al.
Publicado: (2021)

Epidemiological Prevalence of Phenotypical Resistances and Mobilised Colistin Resistance in Avian Commensal and Pathogenic E. coli from Denmark, France, The Netherlands, and the UK
por: Mead, Andrew, et al.
Publicado: (2022)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016)

Dupuytren's contracture: a retrospective database analysis to determine hospitalizations in the Netherlands
por: Overbeek, Jetty A, et al.
Publicado: (2011)

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
por: Ribeiro, Marcos, et al.
Publicado: (2012)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
por: Pelaia, Girolamo, et al.
Publicado: (2015)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
por: Tamura, Tomohiro, et al.
Publicado: (2016)

Systemic glucocorticoid use in Denmark: a population-based prevalence study
por: Laugesen, Kristina, et al.
Publicado: (2017)

Schmallenberg Virus in Zoo Ruminants, France and the Netherlands
por: Laloy, Eve, et al.
Publicado: (2016)

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis
por: McGarvey, Lorcan, et al.
Publicado: (2015)

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD
por: O'Donnell, Denis E., et al.
Publicado: (2017)

Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity
por: Ichinose, Masakazu, et al.
Publicado: (2018)

Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells
por: Yang, Nan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_un634cmd34ophuv962496qafdb